MSD-Backed Ray Locks in $125m to Back Eye Drug Pipeline

Why It Matters

The infusion of capital speeds development of a rhodopsin‑based therapy that could broaden options beyond Luxturna, potentially reshaping the multi‑billion‑dollar retinal disease market.

Key Takeaways

• Ray raises $125M Series B led by Janus Henderson
• Funding targets late‑stage development of RTX‑015 for retinitis pigmentosa
• RTX‑015 delivers rhodopsin, a novel approach versus Luxturna’s RPE65
• RTX‑021 pursues macular conditions including Stargardt disease and geographic atrophy
• RP market attracts multiple gene‑therapy players after Luxturna’s 2017 approval

Pulse Analysis

The eye‑gene‑therapy sector is entering a new phase of capital inflows, with Ray Therapeutics securing a $125 million Series B round that signals confidence in novel approaches to inherited retinal disorders. Retinitis pigmentosa (RP) affects roughly 100,000 Americans, and while Luxturna’s 2017 approval opened the market, its RPE65‑centric mechanism leaves room for alternatives. Ray’s RTX‑015 introduces a rhodopsin delivery platform that bypasses the need to correct specific gene mutations, aiming to restore light‑sensing capability across a broader patient spectrum.

RTX‑015’s mechanism—injecting a light‑sensitive receptor protein into surviving retinal neurons—differs fundamentally from Luxturna’s gene‑replacement strategy. By repurposing existing neurons into functional photoreceptors, Ray hopes to achieve vision improvement even in genetically heterogeneous RP cases. Parallelly, RTX‑021 targets macular conditions such as Stargardt disease and geographic atrophy, employing a similar vector to modulate retinal bipolar cells. Early Phase I/II data will be crucial to validate efficacy and safety, but the dual‑pipeline approach positions Ray to address multiple high‑unmet‑need indications within the ophthalmology market.

Industry observers note a surge in mergers, acquisitions, and strategic alliances around RP assets—ten deals in the past 32 months alone—reflecting the lucrative potential of gene‑therapy solutions. Ray’s financing, backed by established investors like Merck’s venture arm, not only fuels its own development timeline but also intensifies competition for market share. As more candidates progress toward regulatory approval, payers and clinicians will evaluate cost‑effectiveness against existing therapies, potentially driving pricing pressure and broader adoption of gene‑based vision restoration treatments.